The purpose of this study is to demonstrate superiority in survival in favor of TLK286 as compared to active control therapy with Doxil/Caelyx or Hycamtin in the intent-to-treat (ITT) populations.

Inclusion criteria include:

• Considered platinum refractory or resistant according to standard criteria
• Progressed during or following completion of one second-line treatment with Doxil/Caelyx or Hycamtin
• Histologically or cytologically confirmed diagnosis of epithelial cancer of the ovary, fallopian tube, or primary peritoneal cancer
• Measurable disease according to RECIST criteria with documented tumor progression

Exclusion criteria include:

• Treatment with second-line chemotherapy other than Doxil/Caelyx or Hycamtin
• History of whole pelvis radiation therapy within 12 months of enrollment
• Clinically significant cardiac disease
• Evidence of gross hematuria at the time of study entry
• Any signs of intestinal obstruction interfering with nutrition at the time of study entry
• Pregnant or lactating women